Schmidt W A, Wetzel W, Friedländer R, Lange R, Sörensen H F, Lichey H J, Genth E, Mierau R, Gromnica-Ihle E
Medical Centre for Rheumatology, Berlin-Buch, Berlin, Germany.
Clin Rheumatol. 2000;19(5):371-7. doi: 10.1007/s100670070030.
The aim of this study was to compare ELISA, immunodiffusion and immunoblot for the detection of anti-Jo-1 antibodies, and to investigate the association of the results with clinical manifestations. In two medical centres for rheumatology and one for pulmonology, all patients with suspected connective tissue disease were screened over a 5-year period for anti-Jo-1 antibodies by ELISA. Positive sera were controlled in another laboratory by immunodiffusion. If immunodiffusion was negative, sera were controlled again by ELISA. ELISA-positive immunodiffusion-negative sera were tested by immunoblotting. The patients were characterised clinically, and their clinical signs and symptoms were compared with those of 257 patients with anti-Jo-1 antibodies published in 15 case series and 30 case reports. Twenty-five patients had a positive ELISA test. Fifteen sera were positive by ELISA and immunodiffusion (group 1). Three sera showed high titres in both ELISA tests with negative immunodiffusion and immunoblot (group 2). Seven sera showed low titres in both ELISA tests. The results were negative in the other tests (group 3). Patients in groups 1 and 2 could be classified as Jo-1 syndrome patients. Of these 18 patients, 15 had arthritis, 14 had myositis and 14 had interstitial lung disease. Only four patients had myositis at disease onset. We describe four unusual patients with Jo-1 syndrome in detail: 1. Long history of seronegative rheumatoid arthritis; 2. Sjögren's syndrome with Ro- and La-antibodies; 3. Scleroderma and bronchial carcinoma with centromere antibodies; 4. Corticoid-sensitive psychosis. Patients with suspected connective tissue disease may be screened for anti-Jo-1 antibodies by ELISA. It detects some patients that are missed by immunodiffusion. Especially lower ELISA titres should be controlled by another method because of the low specificity of the test. The clinical picture is variable. Most patients have features other than myositis at disease onset.
本研究旨在比较酶联免疫吸附测定(ELISA)、免疫扩散和免疫印迹法检测抗Jo-1抗体,并探讨检测结果与临床表现之间的关联。在两个风湿病医学中心和一个肺病医学中心,对所有疑似结缔组织病的患者在5年期间通过ELISA筛查抗Jo-1抗体。阳性血清在另一个实验室通过免疫扩散进行验证。如果免疫扩散结果为阴性,则再次通过ELISA对血清进行验证。ELISA阳性但免疫扩散阴性的血清通过免疫印迹法进行检测。对患者进行临床特征描述,并将其临床体征和症状与15个病例系列和30篇病例报告中发表的257例抗Jo-1抗体患者的情况进行比较。25例患者ELISA检测呈阳性。15份血清ELISA和免疫扩散均为阳性(第1组)。3份血清在两次ELISA检测中均显示高滴度,但免疫扩散和免疫印迹均为阴性(第2组)。7份血清在两次ELISA检测中均显示低滴度,其他检测结果均为阴性(第3组)。第1组和第2组的患者可归类为Jo-1综合征患者。在这18例患者中,15例有关节炎,14例有肌炎,14例有间质性肺病。只有4例患者在疾病发作时出现肌炎。我们详细描述了4例不寻常的Jo-1综合征患者:1. 血清阴性类风湿关节炎病史较长;2. 伴有Ro和La抗体的干燥综合征;3. 伴有着丝粒抗体的硬皮病和支气管癌;4. 皮质激素敏感型精神病。疑似结缔组织病的患者可通过ELISA筛查抗Jo-1抗体。它能检测出一些免疫扩散遗漏的患者。由于该检测特异性较低,尤其是ELISA低滴度结果应用另一种方法进行验证。临床表现具有多样性。大多数患者在疾病发作时除肌炎外还有其他特征。